Skip to main content
SpringerLink
Log in

Including Pharmaceuticals in Bundled Payments

  • Commentary
  • Published:
Applied Health Economics and Health Policy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Part D is a voluntary program where people pay a premium to join the program. Some retirees have drug coverage from their prior employers while others do not choose to purchase drug coverage. Approximately 30% of Medicare beneficiaries fall into one of these two categories.

References

  1. Russell L, Manning C. The effect of prospective payment on Medicare expenditures. N Engl J Med. 1989;320(7):439–44. https://doi.org/10.1056/NEJM198902163200706.

    Article  CAS  PubMed  Google Scholar 

  2. Sloan F, Morrisey M, Valvona J. Effects of the Medicare prospective payment system on hospital cost containment: an early appraisal. Milbank Q. 1988;66(2):191–220.

    Article  CAS  Google Scholar 

  3. Miller D, Gust C, Dimick J, Birkmeyer N, Skinner J, Birkmeyer J. Large variations in Medicare payments for surgery highlight savings potential from bundled payment programs. Health Aff (Millwood). 2011;30(11):2107–15. https://doi.org/10.1377/hlthaff.2011.0783.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Dummit L, Kahvecioglu D, Marrufo G, et al. Association between hospital participation in a Medicare bundled payment initiative and payments and quality outcomes for lower extremity joint replacement episodes. JAMA. 2016;316(12):1267–78. https://doi.org/10.1001/jama.2016.12717.

    Article  PubMed  Google Scholar 

  5. Dummit L, Marrufo G, Marshall J, et al. CMS bundled payments for care improvement initiative models 24: year 3 evaluation & monitoring annual report. Lewin Group, Falls Church, VA. Oct 2017. Available from: https://downloads.cms.gov/files/cmmi/bpci-models2-4yr3evalrpt.pdf. [Accessed 26 Jun 2022].

  6. Haas D, Zhang X, Kaplan R, Song Z. Evaluation of economic and clinical outcomes under Centers for Medicare & Medicaid Services mandatory bundled payments for joint replacements. JAMA Intern Med. 2019;179(7):924–31. https://doi.org/10.1001/jamainternmed.2019.0480.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Barnett M, Wilcock A, McWilliams J, et al. Two-year evaluation of mandatory bundled payments for joint replacement. N Engl J Med. 2019;380:252–62. https://doi.org/10.1056/NEJMsa1809010.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Navathe A, Troxel A, Liao J, et al. Cost of joint replacement using bundled payment models. JAMA Intern Med. 2017;177(2):214–22. https://doi.org/10.1001/jamainternmed.2016.8263.

    Article  PubMed  Google Scholar 

  9. Finkelstein A, Ji Y, Mahoney N, Skinner J. Mandatory Medicare bundled payment program for lower extremity joint replacement and discharge to institutional postacute care: interim analysis of the first year of a 5-year randomized trial. JAMA. 2018;320(9):892–900. https://doi.org/10.1001/jama.2018.12346.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Joynt Maddox K, Orav E, Zheng J, Epstein A. Evaluation of Medicare’s bundled payments initiative for medical conditions. N Engl J Med. 2018;379(3):260–9. https://doi.org/10.1056/NEJMsa1801569.

    Article  PubMed  Google Scholar 

  11. HHS Office of Inspector General. Update: Medicare payments for end stage renal disease drugs. Mar 24, 2014. Available from: https://oig.hhs.gov/oei/reports/oei-03-12-00550.asp. [Accessed 26 Jun 2022].

  12. Centers for Medicare & Medicaid Services, Department of Health & Human Services. Medicare program; End-Stage Renal Disease Prospective Payment System, and Quality Incentive Program. Final rule, 80(215). Nov 2015. Available from: https://www.govinfo.gov/content/pkg/FR-2015-11-06/pdf/2015-27928.pdf. [Accessed 26 Jun 2022].

  13. Medicare Payment Advisory Commission. Report to the Congress: Medicare payment policy. Mar 2014. Available from: http://www.medpac.gov/docs/default-source/reports/mar14_entirereport.pdf. [Accessed 26 Jun 2022].

  14. Acumen, LLC. Evaluation of patient satisfaction and experience of care for Medicare beneficiaries with end-stage renal disease (ESRD): impact of the ESRD Prospective Payment System (PPS) and ESRD Quality Incentive Program (QIP) final report. Jul 2014. Available from: https://innovation.cms.gov/files/reports/esrd-eval-ptsat.pdf. [Accessed 26 Jun 2022].

  15. Cubanski J, Damico A, Neuman T. 10 Things to know about Medicare Part D coverage and costs in 2019. Kaiser Family Foundation. Jun 4 2019. Available from: https://www.kff.org/medicare/issue-brief/10-things-to-know-about-medicare-part-d-coverage-and-costs-in-2019/. [Accessed 26 Jun 2022].

  16. Evaluation of the oncology care model: performance periods 1–5. Jan 2021. Available from: https://innovation.cms.gov/data-and-reports/2021/ocm-evaluation-pp1-5. [Accessed 26 Jun 2022].

  17. Centers for Medicare and Medicaid Services. MS-DRG classifications and software. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software. [Accessed 26 Jun 2022].

  18. Werble C. Medicare Part B. Health Aff. 2017. https://doi.org/10.1377/hpb20171008.000171.

    Article  Google Scholar 

  19. Butcher L. ASP+6 should go, but what’s next? Oncol Times. 2015;37(12):21–2. https://doi.org/10.1097/01.COT.0000467324.96125.73.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Johns Hopkins Bloomberg School of Public Health, Johns Hopkins School of Medicine, Baltimore, MD, USA

    Gerard F. Anderson

  2. Maryland Prescription Drug Affordability Board, Bowie, MD, USA

    Andrew York

  3. The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA

    Joshua L. Choe

Authors
  1. Gerard F. Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew York
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joshua L. Choe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joshua L. Choe.

Ethics declarations

Funding

Gerard F. Anderson and Joshua L. Choe are funded by John and Laura Arnold Foundation Ventures.

Conflicts of Interest

All authors declare no potential conflicts of interest with respect to the research, authorship, or publication of this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Anderson, G.F., York, A. & Choe, J.L. Including Pharmaceuticals in Bundled Payments. Appl Health Econ Health Policy 20, 625–628 (2022). https://doi.org/10.1007/s40258-022-00742-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40258-022-00742-z

Search

Navigation